← Back
Data updated: Mar 10, 2026
TOLMAR
OncologyGastroenterologyImmunology
TOLMAR is a specialty pharmaceutical company focused on Oncology, Gastroenterology, Immunology. Key products include JATENZO.
2002
Since
6
Drugs
-
Trials
133
Approved (2yr)
Key Drugs
Recent Activity
LEVETIRACETAM 2025-12-02
LEVETIRACETAM 2025-11-21
FENSOLVI KIT 2025-09-23
Labeling
JATENZO 2025-09-12
Labeling
LEVETIRACETAM 2025-08-15
Labeling
LEVETIRACETAM 2025-08-15
Labeling
LEVETIRACETAM 2025-08-12
Labeling
LEVETIRACETAM 2025-08-12
Labeling
LEVETIRACETAM 2025-08-12
Labeling
LEVETIRACETAM 2025-08-06
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 74%
2 drugs Phase 3: 2
Gastroenterology 22%
1 drugs
Immunology 4%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology, Immunology
Discontinued (0)
Company Info
- First Approval
- 2002-01-23
- Latest
- 2025-09-23
- Applications
- 9